Oral LD50 values of doxepin in mouse and rat are 180 mg/kg and 147 mg/kg, respectively.MSDS In an overdose state, symptoms of convulsions, dysrhythmias, coma, severe hypotension, central nervous system depression, changes on electrocardiography results and death have been observed.T249
On fertility studies, doxepin was shown to increase the copulatory interval, decrease the corpora lutea, decrease implantation, decreased the number of viable embryos, decrease litter size, increase the number of abnormal sperm and decrease the sperm motility. There is no evidence indicating carcinogenic and mutagenic potential.FDA label
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties.T559 It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture.T83
In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including amitriptyline, clomipramine, desipramine, imipramine, nortriptyline, protriptyline and trimipramine.L5977
Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.L5971 However, in 2010 it was approved for the treatment of insomnia. The latter indication was presented by Pernix Therapeutics.L5974
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.
The presence of this polymorphism in CYP2C19 is associated with poor metabolism of doxepin.
The presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of doxepin.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.
The presence of this polymorphism in CYP2D6 is associated with reduced or poor metabolism of doxepin.
| Deferasirox | The serum concentration of Doxepin can be increased when it is combined with Deferasirox. |
| Peginterferon alfa-2b | The serum concentration of Doxepin can be increased when it is combined with Peginterferon alfa-2b. |
| Leflunomide | The serum concentration of Doxepin can be decreased when it is combined with Leflunomide. |
| Teriflunomide | The serum concentration of Doxepin can be decreased when it is combined with Teriflunomide. |
| Remikiren | Doxepin may decrease the antihypertensive activities of Remikiren. |
| Guanadrel | Doxepin may decrease the antihypertensive activities of Guanadrel. |
| Olmesartan | Doxepin may decrease the antihypertensive activities of Olmesartan. |
| Minoxidil | Doxepin may decrease the antihypertensive activities of Minoxidil. |
| Trandolapril | Doxepin may decrease the antihypertensive activities of Trandolapril. |
| Benazepril | Doxepin may decrease the antihypertensive activities of Benazepril. |
| Candoxatril | Doxepin may decrease the antihypertensive activities of Candoxatril. |
| Nitroglycerin | Doxepin may decrease the antihypertensive activities of Nitroglycerin. |
| Cryptenamine | Doxepin may decrease the antihypertensive activities of Cryptenamine. |
| Eprosartan | Doxepin may decrease the antihypertensive activities of Eprosartan. |
| Quinapril | Doxepin may decrease the antihypertensive activities of Quinapril. |
| Deserpidine | Doxepin may decrease the antihypertensive activities of Deserpidine. |
| Saprisartan | Doxepin may decrease the antihypertensive activities of Saprisartan. |
| Spirapril | Doxepin may decrease the antihypertensive activities of Spirapril. |
| Diethylnorspermine | Doxepin may decrease the antihypertensive activities of Diethylnorspermine. |
| Temocapril | Doxepin may decrease the antihypertensive activities of Temocapril. |
| Rauwolfia serpentina root | Doxepin may decrease the antihypertensive activities of Rauwolfia serpentina root. |
| Angiotensin 1-7 | Doxepin may decrease the antihypertensive activities of Angiotensin 1-7. |
| Imidapril | Doxepin may decrease the antihypertensive activities of Imidapril. |
| BQ-123 | Doxepin may decrease the antihypertensive activities of BQ-123. |
| Zofenopril | Doxepin may decrease the antihypertensive activities of Zofenopril. |
| Guanoxan | Doxepin may decrease the antihypertensive activities of Guanoxan. |
| Delapril | Doxepin may decrease the antihypertensive activities of Delapril. |
| Vincamine | Doxepin may decrease the antihypertensive activities of Vincamine. |
| Linsidomine | Doxepin may decrease the antihypertensive activities of Linsidomine. |
| Guanoxabenz | Doxepin may decrease the antihypertensive activities of Guanoxabenz. |
| Tolonidine | Doxepin may decrease the antihypertensive activities of Tolonidine. |
| Endralazine | Doxepin may decrease the antihypertensive activities of Endralazine. |
| Cadralazine | Doxepin may decrease the antihypertensive activities of Cadralazine. |
| Bietaserpine | Doxepin may decrease the antihypertensive activities of Bietaserpine. |
| Guanazodine | Doxepin may decrease the antihypertensive activities of Guanazodine. |
| Methoserpidine | Doxepin may decrease the antihypertensive activities of Methoserpidine. |
| Guanoclor | Doxepin may decrease the antihypertensive activities of Guanoclor. |
| Tocopherylquinone | Doxepin may decrease the antihypertensive activities of Tocopherylquinone. |
| Benazeprilat | Doxepin may decrease the antihypertensive activities of Benazeprilat. |
| Fosinoprilat | Doxepin may decrease the antihypertensive activities of Fosinoprilat. |
| Ramiprilat | Doxepin may decrease the antihypertensive activities of Ramiprilat. |
| Perindoprilat | Doxepin may decrease the antihypertensive activities of Perindoprilat. |
| Quinaprilat | Doxepin may decrease the antihypertensive activities of Quinaprilat. |
| Pinacidil | Doxepin may decrease the antihypertensive activities of Pinacidil. |
| Riociguat | Doxepin may decrease the antihypertensive activities of Riociguat. |
| Aliskiren | Doxepin may decrease the antihypertensive activities of Aliskiren. |
| Enalapril | Doxepin may decrease the antihypertensive activities of Enalapril. |
| Captopril | Doxepin may decrease the antihypertensive activities of Captopril. |
| Cilazapril | Doxepin may decrease the antihypertensive activities of Cilazapril. |
| Ambrisentan | Doxepin may decrease the antihypertensive activities of Ambrisentan. |
| Selexipag | Doxepin may decrease the antihypertensive activities of Selexipag. |
| Ramipril | Doxepin may decrease the antihypertensive activities of Ramipril. |
| Perindopril | Doxepin may decrease the antihypertensive activities of Perindopril. |
| Levamlodipine | Doxepin may decrease the antihypertensive activities of Levamlodipine. |
| Azilsartan medoxomil | Doxepin may decrease the antihypertensive activities of Azilsartan medoxomil. |
| Diazoxide | Doxepin may decrease the antihypertensive activities of Diazoxide. |
| Buprenorphine | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Hydrocodone | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Doxepin can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Doxepin may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Orphenadrine | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Pramipexole | Doxepin may increase the sedative activities of Pramipexole. |
| Ropinirole | Doxepin may increase the sedative activities of Ropinirole. |
| Rotigotine | Doxepin may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxepin. |
| Suvorexant | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxepin. |
| Thalidomide | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Doxepin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Dabrafenib | The serum concentration of Doxepin can be decreased when it is combined with Dabrafenib. |
| Aclidinium | The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium. |
| Mianserin | Mianserin may increase the anticholinergic activities of Doxepin. |
| Mirabegron | The risk or severity of urinary retention can be increased when Doxepin is combined with Mirabegron. |
| Potassium chloride | The risk or severity of gastrointestinal ulceration can be increased when Doxepin is combined with Potassium chloride. |
| Pramlintide | The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Doxepin. |
| Secretin porcine | The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Doxepin. |
| Tiotropium | The risk or severity of adverse effects can be increased when Doxepin is combined with Tiotropium. |
| Topiramate | The risk or severity of hyperthermia and oligohydrosis can be increased when Doxepin is combined with Topiramate. |
| Umeclidinium | The risk or severity of adverse effects can be increased when Doxepin is combined with Umeclidinium. |
| Doxapram | The risk or severity of hypertension can be increased when Doxapram is combined with Doxepin. |
| Phenmetrazine | The risk or severity of hypertension can be increased when Phenmetrazine is combined with Doxepin. |
| Omapatrilat | Doxepin may decrease the antihypertensive activities of Omapatrilat. |
| Rescinnamine | Doxepin may decrease the antihypertensive activities of Rescinnamine. |
| Epicaptopril | The risk or severity of hypertension can be increased when Doxepin is combined with Epicaptopril. |
| 1-benzylimidazole | The risk or severity of hypertension can be increased when Doxepin is combined with 1-benzylimidazole. |
| Saralasin | The risk or severity of hypertension can be increased when Doxepin is combined with Saralasin. |
| Tyramine | The risk or severity of hypertension can be increased when Doxepin is combined with Tyramine. |
| Atipamezole | The risk or severity of hypertension can be increased when Doxepin is combined with Atipamezole. |
| Idazoxan | The risk or severity of hypertension can be increased when Doxepin is combined with Idazoxan. |
| Tramazoline | The risk or severity of hypertension can be increased when Doxepin is combined with Tramazoline. |
| Fenozolone | The risk or severity of hypertension can be increased when Doxepin is combined with Fenozolone. |
| Xenon | The risk or severity of hypertension can be increased when Doxepin is combined with Xenon. |